BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$208.85 MLiabilities$1.01 BNon-current liabilities$803.29 MCurrent assets$484.68 MAssets$557.85 MNon-current assets$73.17 MEquity−$454.29 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSShort-term investmentsCash and cash equivalentsTrade receivablesPrepaid expenses and other current assetsInventory, netRestricted cashLong-term inventory, netOther assetsRight of use assets, netProperty and equipment, netAccrued expensesRoyalty financing obligationsShare-based liabilityDeferred revenueAccounts payableOperating lease liabilitiesFinance lease liabilitiesSecured term loanRoyalty financing obligationsDeferred revenueOperating lease liabilitiesFinance lease liabilitiesAdditional paid-in capitalCommon stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding – 255,265 at June 30, 2026 and 213,060 at December 31, 2025Accumulated deficitAccumulated other comprehensive (loss) incomeCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityAccrued expensesAccrued expenses$121.90 MCurrent liabilitiesCurrent liabilities$208.85 MRoyalty financing obligationsRoyalty financing obligations$43.81 MShare-based liabilityShare-based liability$16.36 MDeferred revenueDeferred revenue$12.32 MLiabilitiesLiabilities$1.01 BAccounts payableAccounts payable$11.46 MOperating lease liabilitiesOperating lease liabilities$1.91 MFinance lease liabilitiesFinance lease liabilities$1.09 MNon-current liabilitiesNon-current liabilities$803.29 MSecured term loanSecured term loan$395.40 MRoyalty financing obligationsRoyalty financing obligations$382.98 MDeferred revenueDeferred revenue$13.46 MOperating lease liabilitiesOperating lease liabilities$10.60 MFinance lease liabilitiesFinance lease liabilities$849.00 KCurrent assetsCurrent assets$484.68 MShort-term investmentsShort-term investments$197.60 MAssetsAssets$557.85 MCash and cash equivalentsCash and cash equivalents$154.97 MAdditional paid-in capitalAdditional paid-in capital$1.69 BTrade receivablesTrade receivables$110.76 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$14.82 MInventory, netInventory, net$6.06 MRestricted cashRestricted cash$479.00 KLong-term inventory, netLong-term inventory, net$31.95 MNon-current assetsNon-current assets$73.17 MOther assetsOther assets$19.56 MRight of use assets, netRight of use assets, net$12.61 MProperty and equipment, netProperty and equipment, net$9.06 MEquityEquity−$454.29 MCommon stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding – 255,265 at June 30, 2026 and 213,060 at December 31, 2025Common stock$2.55 MAccumulated deficitAccumulated deficit−$2.15 BAccumulated other comprehensive (loss) incomeAccumulated other comprehensive (loss) income−$528.00 K
Chart details

BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
557,851,000 US dollars
Current assets
484,683,000 US dollars
Non-current assets
73,168,000 US dollars
Liabilities
1,012,140,000 US dollars
Current liabilities
208,846,000 US dollars
Non-current liabilities
803,294,000 US dollars
Equity
negative 454,289,000 US dollars
Short-term investments
197,601,000 US dollars
Cash and cash equivalents
154,972,000 US dollars
Trade receivables
110,757,000 US dollars
Prepaid expenses and other current assets
14,818,000 US dollars
Inventory, net
6,056,000 US dollars
Restricted cash
479,000 US dollars
Long-term inventory, net
31,945,000 US dollars
Other assets
19,557,000 US dollars
Right of use assets, net
12,608,000 US dollars
Property and equipment, net
9,058,000 US dollars
Long-term investments
0 US dollars
Accrued expenses
121,895,000 US dollars
Royalty financing obligations
43,808,000 US dollars
Share-based liability
16,360,000 US dollars
Deferred revenue
12,320,000 US dollars
Accounts payable
11,459,000 US dollars
Operating lease liabilities
1,912,000 US dollars
Finance lease liabilities
1,092,000 US dollars
Secured term loan
395,400,000 US dollars
Royalty financing obligations
382,981,000 US dollars
Deferred revenue
13,461,000 US dollars
Operating lease liabilities
10,603,000 US dollars
Finance lease liabilities
849,000 US dollars
Additional paid-in capital
1,693,282,000 US dollars
Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding – 255,265 at June 30, 2026 and 213,060 at December 31, 2025
2,553,000 US dollars
Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding at June 30, 2026 and December 31, 2025
0 US dollars
Accumulated deficit
negative 2,149,596,000 US dollars
Accumulated other comprehensive (loss) income
negative 528,000 US dollars

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!